Losartan Potassium, 50 mg tablets, 90 count bottle, NDC 60429-317-90

Recall Insight

This FDA Drug action (record #D-1463-2019) was formally reported on July 17, 2019, with the manufacturer initiating the action on June 14, 2019. It is classified under Moderate severity (Class II), with a current status of Terminated. Golden State Medical Supply Inc. is listed as the recalling firm, operating out of Camarillo, CA. Federal records indicate 14,955 bottles (1,345,950 tablets) units are affected, placing this recall in the million-unit bracket that typically triggers nationwide consumer alerts and retailer sweeps.

The documented reason for this recall is: CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products. Distribution data in the federal record shows the product reached: US Nationwide One (1) US government account. No foreign accounts.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

To put this record in context, PlainRecalls indexes 83,949 recalls across the FDA, CPSC, NHTSA and USDA FSIS going back to 1995. Within the same product category, the database holds 6 closely related recalls, of which 5 were also issued by FDA Drug. That clustering is a signal — repeated actions in a narrow category often indicate a systemic quality-control issue, a supplier-wide contamination, or a design defect that has propagated across product lines. This recall is roughly 7 years old; older recalls can remain relevant because many units enter resale, rental, and secondary-market channels where the original warning never reaches the end user. Always cross-check the recall number against the official agency page before relying on any summary.